8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
If January offered excitement, promise and hope for a busy year of pharma M&A ahead, then February has more than tempered those expectations. 2 March 2023
The developers of the newly-approved hemophilia A therapy Altuviiio (efanesoctocog alfa) have announced positive results from the Phase III XTEND-Kids trial. 2 March 2023
In 2022, generic drugs remained a significant public health priority for the US Food and Drug Administration (FDA), the agency announced yesterday, along with publishing its 2022 Office of Generic Drugs (OGD) Annual Report. 2 March 2023
The influential Institute for Clinical and Economic Review (ICER), a Boston, USA-based pricing watchdog, has released a report into the cost-effectiveness of Leqembi (lecanemab). 1 March 2023
The political news this week in the UK is full of Prime Minister Rishi Sunak’s deal with the European, commented Ropes & Gray private equity counsel David Dowling. 1 March 2023
Shares of US biotech Cidara Therapeutics rose almost 20% to $1.81 in early trading as the company announced promising efficacy and safety data from a planned interim analysis of the ongoing Phase IIa trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain, as of a February 13, 2023 data cut-off. 1 March 2023
Eager to boost the development of orphan drugs to treat rare diseases in India, the government is looking to offer incentives to drug companies in terms of faster approvals and extended periods of exclusivity. 1 March 2023
The European Commission has granted marketing authorization for Nubeqa (darolutamide) alongside androgen deprivation therapy in combination with docetaxel, to treat metastatic hormone-sensitive prostate cancer (mHSPC). 1 March 2023
Shanghai Junshi Biosciences had more positive news, this time on its monoclonal antibody (MAb) candidate ongericimab, adding to the successful trials results for its toripalimab in breast cancer last week. 1 March 2023
The US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) yesterday voted that available data is adequate to support the safety and effectiveness of the respiratory syncytial virus (RSV) bivalent vaccine candidate PF-06928316 or RSVpreF, from US pharma giant Pfizer. 1 March 2023
In a second financing within one year, China-based Oricell Therapeutics has announced the close of a $45 million Series B1 investment round. This adds to the $125 million Series B fund that was raised in July 2022. 1 March 2023
The Association of the British Pharmaceutical Industry (ABPI) has attempted to show that there is a better way than the existing Voluntary Pricing and Access Scheme (VPAS). 1 March 2023
US generic drug-focussed drugmaker Viatris has announced that, as it prepares to enter Phase 2 of its previously revealed strategic plan in 2024, the appointment of pharma veteran Scott Smith to lead the execution of that plan as Viatris' new chief executive (CEO), effective April 1, 2023. 28 February 2023
Werner Baumann, chairman of the board of management at the German life sciences major Bayer, presented his final set of annual financial results on Tuesday. 28 February 2023
US precision medicines company Frontier Medicines today announced the addition of Christo Shalish to the leadership team as senior vice president (SVP) and head of business development. 28 February 2023
Sino-American biotech BeiGene yesterday reported financial results, showing that revenues for the fourth quarter and full year 2022 was $380.1 million, missing consensus estimates of $345 million by 2%, and $1.4 billion, respectively, compared to $214.0 million and $1.2 billion in the prior-year periods. 28 February 2023
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.